Therapy of Angiosarcoma with Thalidomide and Lenalidomide.

Area of Science:

• Oncology
• Medical Case Study

Background:

• Angiosarcoma is a rare cancer with limited systemic treatment options for metastatic disease.
• Prognosis for metastatic angiosarcoma is generally poor, necessitating novel therapeutic approaches.

Observation:

• A 73-year-old male with metastatic angiosarcoma, who progressed after immunotherapy, was treated with thalidomide.
• Thalidomide provided stable disease for 9 months but caused severe neuropathy.

Findings:

• Lenalidomide, substituted for thalidomide due to side effects, maintained stable disease for over 16 months.
• This represents the first reported case of effective lenalidomide treatment in angiosarcoma.

Implications:

• Lenalidomide shows promise as a therapeutic option for metastatic angiosarcoma.
• Further clinical investigation into lenalidomide for angiosarcoma management is warranted.